Background: Physicians may encounter situations where they need to co-administer omalizumab with non-IgE-targeting monoclonal antibodies. In this study, we share our experience with these dual biologic treatments.

Objective: To evaluate the efficacy and safety of dual biological therapy using omalizumab and non-IgE-targeting monoclonal antibodies at a single center.

Methods: We retrospectively reviewed the medical records of adults treated with a dual biological therapy regimen consisting of omalizumab and another biologic between 2020 and 2022.

Results: Our review identified nine patients (age range: 51-75 years, 7 women and 2 men) who were treated with omalizumab for high Th2 disorders, including chronic spontaneous urticaria (n = 7) and asthma (n = 2). Seven patients received a second biologic for co-existing non-Th2 disorders, while two received an additional biologic to better control their Th2-mediated disorders. The patients were treated with the following biologics: anti-IL-5 agents (mepolizumab [n = 1] and benralizumab [n = 1]), the IL-4/13 inhibitor dupilumab (n = 1), the anti-IL-17 biologic secukinumab (n = 1), the IL-1 inhibitor anakinra (n = 1), the anti-calcitonin gene-related peptide agent fremanezumab (n = 1), and anti-TNF-α agents (etanercept [n = 1], golimumab [n = 1], and adalimumab [n = 1]). Dual biotherapy was administered for 3-34 months with observed clinical improvement. No adverse events or infections were reported.

Conclusions: Dual biological treatment with omalizumab and another biologic appears to be safe, with no need to discontinue non-IgE-targeting agents during omalizumab therapy.

Keywords: Biologics; Biotherapy; Dual biologics; IgE; Omalizumab.

© 2025. The Author(s).

背景：

医生可能会遇到需要同时使用奥马珠单抗与非IgE靶向的单克隆抗体的情况。在这项研究中，我们分享了关于这两种双生物制剂治疗的经验。

目的：

评估单一中心内奥马珠单抗和非IgE靶向单克隆抗体联合使用双重生物疗法的有效性和安全性。

方法：

我们回顾性地审查了2020年至2022年间接受由奥马珠单抗与其他一种生物制剂组成的双生物治疗方案的成人的医疗记录。

结果：

我们的审查确定了九名患者（年龄范围：51-75岁，其中7名为女性和2名为男性），他们因高Th2疾病接受了奥马珠单抗治疗，包括慢性自发性荨麻疹（n = 7）和哮喘（n = 2）。七名患者为了同时存在的非Th2疾病而接受了一种第二种生物制剂，而两名患者则为了更好地控制其由Th2介导的疾病而接受了一种额外的生物制剂。这些患者接受了以下生物制剂：抗IL-5药物（美泊利单抗[n = 1]和班纳里珠单抗[n = 1]）、IL-4/13抑制剂度普利尤单抗(n = 1)、抗IL-17的生物制剂苏金单抗(n = 1)、IL-1抑制剂阿那白滞素(n = 1)、降钙素基因相关肽药物弗雷马珠单抗(n = 1)，以及抗TNF-α药物（依那西普[n = 1]，戈利木单抗[n = 1]和阿达木单抗[n = 1]）。双生物治疗持续了3至34个月，并观察到临床改善。未报告任何不良事件或感染。

结论：

奥马珠单抗与另一种生物制剂的双重生物治疗似乎是安全的，在接受奥马珠单抗治疗期间无需停止使用非IgE靶向药物。

关键词：

生物制剂；生物疗法；双生物制剂；IgE；奥马珠单抗。